Cutaneous vaccination: The skin as an immunologically active tissue and the challenge of antigen delivery

Journal of Controlled Release

Volumn 66, Issue 2-3, 2000, Pages 199-214

  Babiuk, Shawn ^a   Baca Estrada, Maria ^a,b   Babiuk, Lorne A ^b   Ewen, Catherine ^b   Foldvari, Marianna ^a  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

^b UNIVERSITY OF SASKATCHEWAN   (Canada)

Author keywords

Delivery; Liposomes; Skin; Transdermal; Vaccines

Indexed keywords

ANTIGEN; DNA VACCINE; LIPOSOME; PLASMID DNA; POLYCATION; POLYGLACTIN; POLYLACTIC ACID; POLYMER; VACCINE; VIRUS VACCINE;

CONFOCAL MICROSCOPY; DRUG DELIVERY SYSTEM; HUMAN; IMMUNE RESPONSE; LANGERHANS CELL; MEASLES; MICROENCAPSULATION; MOLECULAR WEIGHT; NONHUMAN; POLIOMYELITIS; PRIORITY JOURNAL; REVIEW; SKIN; TECHNIQUE; VACCINATION;

EID: 0034657049     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-3659(99)00274-6     Document Type: Article

References (136)

1. Hooke A.M., Bellanti J.A., Oeschger M.P. Live attenuated bacterial vaccines: new approaches for safety and efficacy. Lancet. 1:1985;1472-1474.
2. Dertzbaugh M.T. Genetically engineered vaccines: an overview. Plasmid. 39:1998;100-113.
3. Gupta R.K., Relyveld E.H., Lindblad E.B., Bizzini B., Ben-Efraim S., Gupta C.K. Adjuvants - a balance between toxicity and adjuvanticity. Vaccine. 11:1993;293-306.
4. Klinman D.M., Yi A.K., Beaucage S.L., Conover J., Krieg A.M. CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma. Proc. Natl. Acad. Sci. USA. 93:1996;2879-2883.
5. Gregoriadis G. Immunological adjuvants: a role for liposomes. Immunol. Today. 11:1990;89-97.
6. Mackett M., Cox C., Pepper S.D., Lees J.F., Naylor B.A., Wedderburn N., Arrand J.R. Immunisation of common marmosets with vaccinia virus expressing Epstein-Barr virus (EBV) gp340 and challenge with EBV. J. Med. Virol. 50:1996;263-271.
7. Reddy P.S., Idamakanti N., Hyun B.H., Tikoo S.K., Babiuk L.A. Development of porcine adenovirus-3 as an expression vector. J. Gen. Virol. 80:1999;563-570.
8. Kaper J.B., Lockman H., Baldini M.M., Levine M.M. Recombinant nontoxinogenic Vibrio cholerae strains as attenuated cholera vaccine candidates. Nature. 308:1984;655-658.
9. Lubroth J., Grubman M.J., Burrage T.G., Newman J.F., Brown F. Absence of protein 2C from clarified foot-and-mouth disease virus vaccines provides the basis for distinguishing convalescent from vaccinated animals. Vaccine. 14:1996;419-427.
10. Johnson D.C. Adenovirus vectors as potential vaccines against herpes simplex virus. Rev. Infect. Dis. 13:(Suppl. 11):1991;S912-916.
11. Rupprecht C.E., Wiktor T.J., Johnston D.H., Hamir A.N., Dietzschold B., Wunner W.H., Glickman L.T., Koprowski H. Oral immunization and protection of raccoons (Procyon lotor) with a vaccinia-rabies glycoprotein recombinant virus vaccine. Proc. Natl. Acad. Sci. USA. 83:1986;7947-7950.
12. Brochier B., Aubert M.F., Pastoret P.P., Masson E., Schon J., Lombard M., Chappuis G., Languet B., Desmettre P. Field use of a vaccinia-rabies recombinant vaccine for the control of sylvatic rabies in Europe and North America. Rev. Sci. Tech. 15:1996;947-970.
13. Kuklin N., Daheshia M., Karem K., Manickan E., Rouse B.T. Induction of mucosal immunity against herpes simplex virus by plasmid DNA immunization. J. Virol. 71:1997;3138-3145.
14. Ulmer J.B., Montgomery D.L., Tang A., Zhu L., Deck R.R., DeWitt C., Denis O., Orme I., Content J., Huygen K. DNA vaccines against tuberculosis. Novartis Found. Symp. 217:1998;239-246.
15. Davis H.L. DNA-based immunization against hepatitis B: experience with animal models. Curr. Top. Microbiol. Immunol. 226:1998;57-68.
16. Ulmer J.B., Donnelly J.J., Parker S.E., Rhodes G.H., Felgner P.L., Dwarki V.J., Gromkowski S.H., Deck R.R., DeWitt C.M., Friedman A., et al. Heterologous protection against influenza by injection of DNA encoding a viral protein (see comments). Science. 259:1993;1745-1749.
17. Tang D.C., DeVit M., Johnston S.A. Genetic immunization is a simple method for eliciting an immune response. Nature. 356:1992;152-154.
18. Yokoyama M., Zhang J., Whitton J.L. DNA immunization: effects of vehicle and route of administration on the induction of protective antiviral immunity. FEMS Immunol. Med. Microbiol. 14:1996;221-230.
19. Roy K., Mao H.Q., Huang S.K., Leong K.W. Oral gene delivery with chitosan-DNA nanoparticles generates immunologic protection in a murine model of peanut allergy. Nat. Med. 5:1999;387-391.
20. Okada E., Sasaki S., Ishii N., Aoki I., Yasuda T., Nishioka K., Fukushima J., Miyazaki J., Wahren B., Okuda K. Intranasal immunization of a DNA vaccine with IL-12- and granulocyte-macrophage colony-stimulating factor (GM-CSF)-expressing plasmids in liposomes induces strong mucosal and cell-mediated immune responses against HIV-1 antigens. J. Immunol. 159:1997;3638-3647.
21. Degano P., Sarphie D.F., Bangham C.R. Intradermal DNA immunization of mice against influenza A virus using the novel PowderJect system. Vaccine. 16:1998;394-398.
22. Alarcon J.B., Waine G.W., McManus D.P. DNA vaccines: technology and application as anti-parasite and anti- microbial agents. Adv. Parasitol. 42:1999;343-410.
23. Srikiatkhachorn A., Braciale T.J. Virus-specific CD8+ T lymphocytes downregulate T helper cell type 2 cytokine secretion and pulmonary eosinophilia during experimental murine respiratory syncytial virus infection. J. Exp. Med. 186:1997;421-432.
24. Bodey B., Bodey B. Jr., Kaiser H.E. Dendritic type, accessory cells within the mammalian thymic microenvironment. Antigen presentation in the dendritic neuro-endocrine-immune cellular network. In Vivo. 11:1997;351-370.
25. Eckert R.L. Structure, function, and differentiation of the keratinocyte. Physiol. Rev. 69:1989;1316-1346.
26. Stanley J.R., Woodley D.T., Katz S.I., Martin G.R. Structure and function of basement membrane. J. Invest. Dermatol. 79:(Suppl. 1):1982;69s-72s.
27. Fuchs E. Keratins and the skin. Annu. Rev. Cell. Dev. Biol. 11:1995;123-153.
28. Chapman S.J., Walsh A. Desmosomes, corneosomes and desquamation. An ultrastructural study of adult pig epidermis. Arch. Dermatol. Res. 282:1990;304-310.
29. Elias P.M. Epidermal lipids, barrier function, and desquamation. J. Invest. Dermatol. 80:(Suppl.):1983;44s-49s.
30. Tsai J.C., Guy R.H., Thornfeldt C.R., Gao W.N., Feingold K.R., Elias P.M. Metabolic approaches to enhance transdermal drug delivery. 1. Effect of lipid synthesis inhibitors. J. Pharm. Sci. 85:1996;643-648.
31. Luger T.A., Schwarz T. Therapeutic use of cytokines in dermatology. J. Am. Acad. Dermatol. 24:1991;915-926.
32. Lawley T.J., Kubota Y. Cell adhesion molecules and cutaneous inflammation. Semin. Dermatol. 10:1991;256-259.
33. Cumberbatch M., Dearman R.J., Kimber I. Adhesion molecule expression by epidermal Langerhans cells and lymph node dendritic cells: a comparison. Arch. Dermatol. Res. 288:1996;739-744.
34. Romani N., Koide S., Crowley M., Witmer-Pack M., Livingstone A.M., Fathman C.G., Inaba K., Steinman R.M. Presentation of exogenous protein antigens by dendritic cells to T cell clones. Intact protein is presented best by immature, epidermal Langerhans cells. J. Exp. Med. 169:1989;1169-1178.
35. Celluzzi C.M., Falo L.D. Jr. Epidermal dendritic cells induce potent antigen-specific CTL-mediated immunity. J. Invest. Dermatol. 108:1997;716-720.
36. Barry M.A., Johnston S.A. Biological features of genetic immunization. Vaccine. 15:1997;788-791.
37. Condon C., Watkins S.C., Celluzzi C.M., Thompson K., Falo L.D. Jr. DNA-based immunization by in vivo transfection of dendritic cells. Nat. Med. 2:1996;1122-1128.
38. Tuting T., DeLeo A.B., Lotze M.T., Storkus W.J. Genetically modified bone marrow-derived dendritic cells expressing tumor-associated viral or 'self' antigens induce antitumor immunity in vivo. Eur. J. Immunol. 27:1997;2702-2707.
39. Klinman D.M., Sechler J.M., Conover J., Gu M., Rosenberg A.S. Contribution of cells at the site of DNA vaccination to the generation of antigen-specific immunity and memory. J. Immunol. 160:1998;2388-2392.
40. Maecker H.T., Umetsu D.T., DeKruyff R.H., Levy S. Cytotoxic T cell responses to DNA vaccination: dependence on antigen presentation via class II MHC. J. Immunol. 161:1998;6532-6536.
41. Chen Y., Webster R.G., Woodland D.L. Induction of CD8+ T cell responses to dominant and subdominant epitopes and protective immunity to Sendai virus infection by DNA vaccination. J. Immunol. 160:1998;2425-2432.
42. Fynan E.F., Webster R.G., Fuller D.H., Haynes J.R., Santoro J.C., Robinson H.L. DNA vaccines: protective immunizations by parenteral, mucosal, and gene-gun inoculations. Proc. Natl. Acad. Sci. USA. 90:1993;11478-11482.
43. Pertmer T.M., Eisenbraun M.D., McCabe D., Prayaga S.K., Fuller D.H., Haynes J.R. Gene gun-based nucleic acid immunization: elicitation of humoral and cytotoxic T lymphocyte responses following epidermal delivery of nanogram quantities of DNA. Vaccine. 13:1995;1427-1430.
44. Bleasdale H.N. B.C.G. vaccination by jet injection. Tubercle. 46:1965;417-419.
45. Whittle H.C., Lamb W.H., Ryder R.W. Trials of intradermal hepatitis B vaccines in Gambian children. Ann. Trop. Paediatr. 7:1987;6-9.
46. Furth P.A., Shamay A., Hennighausen L. Gene transfer into mammalian cells by jet injection. Hybridoma. 14:1995;149-152.
47. Henry S., McAllister D.V., Allen M.G., Prausnitz M.R. Microfabricated microneedles: a novel approach to transdermal drug delivery. J. Pharm. Sci. 87:1998;922-925.
48. Zhang L., Li L., Hoffmann G.A., Hoffman R.M. Depth-targeted efficient gene delivery and expression in the skin by pulsed electric fields: an approach to gene therapy of skin aging and other diseases. Biochem. Biophys. Res. Commun. 220:1996;633-636.
49. Banga A.K., Prausnitz M.R. Assessing the potential of skin electroporation for the delivery of protein- and gene-based drugs. Trends Biotechnol. 16:1998;408-412.
50. Oldenburg K.R., Vo K.T., Smith G.A., Selick H.E. Iontophoretic delivery of oligonucleotides across full thickness hairless mouse skin. J. Pharm. Sci. 84:1995;915-921.
51. Mitragotri S., Edwards D.A., Blankschtein D., Langer R. A mechanistic study of ultrasonically-enhanced transdermal drug delivery. J. Pharm. Sci. 84:1995;697-706.
52. Mitragotri S., Blankschtein D., Langer R. Ultrasound-mediated transdermal protein delivery. Science. 269:1995;850-853.
53. Lee S., McAuliffe D.J., Flotte T.J., Kollias N., Doukas A.G. Photomechanical transcutaneous delivery of macromolecules. J. Invest. Dermatol. 111:1998;925-929.
54. Heritage P.L., Loomes L.M., Jianxiong J., Brook M.A., Underdown B.J., McDermott M.R. Novel polymer-grafted starch microparticles for mucosal delivery of vaccines. Immunology. 88:1996;162-168.
55. Heritage P.L., Underdown B.J., Brook M.A., McDermott M.R. Oral administration of polymer-grafted starch microparticles activates gut-associated lymphocytes and primes mice for a subsequent systemic antigen challenge. Vaccine. 16:1998;2010-2017.
56. Bowersock T.L., HogenEsch H., Suckow M., Guimond P., Martin S., Borie D., Torregrosa S., Park H., Park K. Oral vaccination of animals with antigens encapsulated in alginate microspheres (in process citation). Vaccine. 17:1999;1804-1811.
57. Truong-Le V.L., August J.T., Leong K.W. Controlled gene delivery by DNA-gelatin nanospheres. Hum. Gene Ther. 9:1998;1709-1717.
58. Jain R., Shah N.H., Malick A.W., Rhodes C.T. Controlled drug delivery by biodegradable poly(ester) devices: different preparative approaches. Drug. Dev. Ind. Pharm. 24:1998;703-727.
59. Jameela S.R., Suma N., Jayakrishnan A. Protein release from poly(epsilon-caprolactone) microspheres prepared by melt encapsulation and solvent evaporation techniques: a comparative study. J. Biomater. Sci. Polym. Ed. 8:1997;457-466.
60. Chiba M., Hanes J., Langer R. Controlled protein delivery from biodegradable tyrosine-containing poly(anhydride-co-imide) microspheres. Biomaterials. 18:1997;893-901.
61. Andrianov A.K., Chen J., Payne L.G. Preparation of hydrogel microspheres by coacervation of aqueous polyphosphazene solutions. Biomaterials. 19:1998;109-115.
62. Truong-Le V.L., Walsh S.M., Schweibert E., Mao H.Q., Guggino W.B., August J.T., Leong K.W. Gene transfer by DNA-gelatin nanospheres. Arch. Biochem. Biophys. 361:1999;47-56.
63. Moser C.A., Speaker T.J., Offit P.A. Effect of microencapsulation on immunogenicity of a bovine herpes virus glycoprotein and inactivated influenza virus in mice. Vaccine. 15:1997;1767-1772.
64. Bowersock T.L., HogenEsch H., Torregrosa S., Borie D., Wang B., Park H., Park K. Induction of pulmonary immunity in cattle by oral administration of ovalbumin in alginate microspheres. Immunol. Lett. 60:1998;37-43.
65. Aggarwal N., HogenEsch H., Guo P., North A., Suckow M., Mittal S.K. Biodegradable alginate microspheres as a delivery system for naked DNA. Can. J. Vet. Res. 63:1999;148-152.
66. Coombes A.G., Yeh M.K., Lavelle E.C., Davis S.S. The control of protein release from poly(DL-lactide co-glycolide) microparticles by variation of the external aqueous phase surfactant in the water-in oil-in water method. J. Control. Release. 52:1998;311-320.
67. Gupta R.K., Chang A.C., Siber G.R. Biodegradable polymer microspheres as vaccine adjuvants and delivery systems. Dev. Biol. Stand. 92:1998;63-78.
68. Jones D.H., Clegg J.C., Farrar G.H. Oral delivery of micro-encapsulated DNA vaccines. Dev. Biol. Stand. 92:1998;149-155.
69. Jones D.H., Corris S., McDonald S., Clegg J.C., Farrar G.H. Poly(DL-lactide-co-glycolide)-encapsulated plasmid DNA elicits systemic and mucosal antibody responses to encoded protein after oral administration. Vaccine. 15:1997;814-817.
70. Cleland J.L. Single-administration vaccines: controlled-release technology to mimic repeated immunizations. Trends Biotechnol. 17:1999;25-29.
71. Kabanov A.V. Taking polycation gene delivery systems from in vitro to in vivo. Pharm. Sci. Technol. Today. 2:1999;365-372.
72. Bielinska A., Kukowska-Latallo J.F., Johnson J., Tomalia D.A., Baker J.R. Jr. Regulation of in vitro gene expression using antisense oligonucleotides or antisense expression plasmids transfected using starburst PAMAM dendrimers. Nucleic Acids Res. 24:1996;2176-2182.
73. Rajananthanan P., Attard G.S., Sheikh N.A., Morrow W.J. Novel aggregate structure adjuvants modulate lymphocyte proliferation and Th1 and Th2 cytokine profiles in ovalbumin immunized mice. Vaccine. 18:1999;140-152.
74. Boussif O., Lezoualc'h F., Zanta M.A., Mergny M.D., Scherman D., Demeneix B., Behr J.P. A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. Proc. Natl. Acad. Sci. USA. 92:1995;7297-7301.
75. van de Wetering P., Cherng J.Y., Talsma H., Crommelin D.J., Hennink W.E. 2-(Dimethylamino)ethyl methacrylate based (co)polymers as gene transfer agents. J. Control. Release. 53:1998;145-153.
76. Pouton C.W., Lucas P., Thomas B.J., Uduehi A.N., Milroy D.A., Moss S.H. Polycation-DNA complexes for gene delivery: a comparison of the biopharmaceutical properties of cationic polypeptides and cationic lipids. J. Control. Release. 53:1998;289-299.
77. Gottschalk S., Sparrow J.T., Hauer J., Mims M.P., Leland F.E., Woo S.L., Smith L.C. A novel DNA-peptide complex for efficient gene transfer and expression in mammalian cells. Gene Ther. 3:1996;48-57.
78. Wadhwa M.S., Collard W.T., Adami R.C., McKenzie D.L., Rice K.G. Peptide-mediated gene delivery: influence of peptide structure on gene expression. Bioconjug. Chem. 8:1997;81-88.
79. Gaur A., Wiers B., Liu A., Rothbard J., Fathman C.G. Amelioration of autoimmune encephalomyelitis by myelin basic protein synthetic peptide-induced anergy. Science. 258:1992;1491-1494.
80. Choi Y.H., Liu F., Park J.S., Kim S.W. Lactose-poly(ethylene glycol)-grafted poly-L-lysine as hepatoma cell-targeted gene carrier. Bioconjug. Chem. 9:1998;708-718.
81. Kim J.S., Kim B.I., Maruyama A., Akaike T., Kim S.W. A new non-viral DNA delivery vector: the terplex system. J. Control. Release. 53:1998;175-182.
82. Anwer K., Earle K.A., Shi M., Wang J., Mumper R.J., Proctor B., Jansa K., Ledebur H.C., Davis S., Eaglstein W., Rolland A.P. Synergistic effect of formulated plasmid and needle-free injection for genetic vaccines. Pharm. Res. 16:1999;889-895.
83. Taylor R.L., Williams D.M., Craven P.C., Graybill J.R., Drutz D.J., Magee W.E. Amphotericin B in liposomes: a novel therapy for histoplasmosis. Am. Rev. Respir. Dis. 125:1982;610-611.
84. Nabel G.J., Nabel E.G., Yang Z.Y., Fox B.A., Plautz G.E., Gao X., Huang L., Shu S., Gordon D., Chang A.E. Direct gene transfer with DNA-liposome complexes in melanoma: expression, biologic activity, and lack of toxicity in humans. Proc. Natl. Acad. Sci. USA. 90:1993;11307-11311.
85. Nabel E.G., Yang Z., Muller D., Chang A.E., Gao X., Huang L., Cho K.J., Nabel G.J. Safety and toxicity of catheter gene delivery to the pulmonary vasculature in a patient with metastatic melanoma. Hum. Gene Ther. 5:1994;1089-1094.
86. Baca-Estrada M.E., Foldvari M., Snider M., van Drunen Littel-van den Hurk S., Babiuk L.A. Effect of IL-4 and IL-12 liposomal formulations on the induction of immune response to bovine herpesvirus type-1 glycoprotein D. Vaccine. 15:1997;1753-1760.
87. Griffiths G.D., Bailey S.C., Hambrook J.L., Keyte M.P. Local and systemic responses against ricin toxin promoted by toxoid or peptide vaccines alone or in liposomal formulations. Vaccine. 16:1998;530-535.
88. Kwak L.W., Pennington R., Boni L., Ochoa A.C., Robb R.J., Popescu M.C. Liposomal formulation of a self lymphoma antigen induces potent protective antitumor immunity. J. Immunol. 160:1998;3637-3641.
89. Baca-Estrada M.E., Foldvari M., Snider M. Induction of mucosal immune responses by administration of liposome-antigen formulations and interleukin-12 (in process citation). J. Interferon Cytokine Res. 19:1999;455-462.
90. Walker C., Selby M., Erickson A., Cataldo D., Valensi J.P., Van Nest G.V. Cationic lipids direct a viral glycoprotein into the class I major histocompatibility complex antigen-presentation pathway. Proc. Natl. Acad. Sci. USA. 89:1992;7915-7918.
91. Bangham A.D. Surrogate cells or Trojan horses. The discovery of liposomes. Bioessays. 17:1995;1081-1088.
92. May S., Ben-Shaul A. DNA-lipid complexes: stability of honeycomb-like and spaghetti-like structures. Biophys. J. 73:1997;2427-2440.
93. Koltover I., Salditt T., Radler J.O., Safinya C.R. An inverted hexagonal phase of cationic liposome-DNA complexes related to DNA release and delivery. Science. 281:1998;78-81.
94. Kirjavainen M., Urtti A., Valjakka-Koskela R., Kiesvaara J., Monkkonen J. Liposome-skin interactions and their effects on the skin permeation of drugs. Eur. J. Pharm. Sci. 7:1999;279-286.
95. Kirjavainen M., Urtti A., Jaaskelainen I., Suhonen T.M., Paronen P., Valjakka-Koskela R., Kiesvaara J., Monkkonen J. Interaction of liposomes with human skin in vitro - the influence of lipid composition and structure. Biochim. Biophys. Acta. 1304:1996;179-189.
96. Filion M.C., Phillips N.C. Toxicity and immunomodulatory activity of liposomal vectors formulated with cationic lipids toward immune effector cells. Biochim. Biophys. Acta. 1329:1997;345-356.
97. Wattiaux R., Jadot M., Warnier-Pirotte M.T., Wattiaux-De Coninck S. Cationic lipids destabilize lysosomal membrane in vitro. FEBS Lett. 417:1997;199-202.
98. McLachlan G., Davidson D.J., Stevenson B.J., Dickinson P., Davidson-Smith H., Dorin J.R., Porteous D.J. Evaluation in vitro and in vivo of cationic liposome-expression construct complexes for cystic fibrosis gene therapy. Gene Ther. 2:1995;614-622.
99. van der Woude I., Visser H.W., ter Beest M.B., Wagenaar A., Ruiters M.H., Engberts J.B., Hoekstra D. Parameters influencing the introduction of plasmid DNA into cells by the use of synthetic amphiphiles as a carrier system. Biochim. Biophys. Acta. 1240:1995;34-40.
100. San H., Yang Z.Y., Pompili V.J., Jaffe M.L., Plautz G.E., Xu L., Felgner J.H., Wheeler C.J., Felgner P.L., Gao X., et al. Safety and short-term toxicity of a novel cationic lipid formulation for human gene therapy. Hum. Gene Ther. 4:1993;781-788.
101. Zhao D.D., Watarai S., Lee J.T., Kouchi S., Ohmori H., Yasuda T. Gene transfection by cationic liposomes: comparison of the transfection efficiency of liposomes prepared from various positively charged lipids. Acta Med. Okayama. 51:1997;149-154.
102. Klavinskis L.S., Gao L., Barnfield C., Lehner T., Parker S. Mucosal immunization with DNA-liposome complexes. Vaccine. 15:1997;818-820.
103. Ishii N., et al. Cationic liposomes are a strong adjuvant for a DNA vaccine of human immunodeficiency virus type 1. AIDS Res. Hum. Retroviruses. 13:1997;1421-1428.
104. Gregoriadis G., Saffie R., de Souza J.B. Liposome-mediated DNA vaccination. FEBS Lett. 402:1997;107-110.
105. Kirnbauer R., Chandrachud L.M., O'Neil B.W., Wagner E.R., Grindlay G.J., Armstrong A., McGarvie G.M., Schiller J.T., Lowy D.R., Campo M.S. Virus-like particles of bovine papillomavirus type 4 in prophylactic and therapeutic immunization. Virology. 219:1996;37-44.
106. Conner M.E., Crawford S.E., Barone C., O'Neal C., Zhou Y.J., Fernandez F., Parwani A., Saif L.J., Cohen J., Estes M.K. Rotavirus subunit vaccines. Arch. Virol. Suppl. 12:1996;199-206.
107. Sedlik C., Saron M., Sarraseca J., Casal I., Leclerc C. Recombinant parvovirus-like particles as an antigen carrier: a novel nonreplicative exogenous antigen to elicit protective antiviral cytotoxic T cells. Proc. Natl. Acad. Sci. USA. 94:1997;7503-7508.
108. Schirmbeck R., Bohm W., Reimann J. Virus-like particles induce MHC class I-restricted T-cell responses. Lessons learned from the hepatitis B small surface antigen. Intervirology. 39:1996;111-119.
109. Bachmann M.F., Zinkernagel R.M. Neutralizing antiviral B cell responses. Annu. Rev. Immunol. 15:1997;235-270.
110. Kingsman S.M., Kingsman A.J. Polyvalent recombinant antigens: a new vaccine strategy. Vaccine. 6:1988;304-306.
111. Allsopp C.E., Plebanski M., Gilbert S., Sinden R.E., Harris S., Frankel G., Dougan G., Hioe C., Nixon D., Paoletti E., Layton G., Hill A.V. Comparison of numerous delivery systems for the induction of cytotoxic T lymphocytes by immunization. Eur. J. Immunol. 26:1996;1951-1959.
112. Adams S.E., Burns N.R., Layton G.T., Kingsman A.J. Hybrid Ty virus-like particles. Int. Rev. Immunol. 11:1994;133-141.
113. Touze A., Coursaget P. In vitro gene transfer using human papillomavirus-like particles. Nucleic Acids Res. 26:1998;1317-1323.
114. Frenchick P.J., Sabara M.I., Ready K.F., Babiuk L.A. Biochemical and immunological characterization of a novel peptide carrier system using rotavirus VP6 particles. Vaccine. 10:1992;783-791.
115. Theves G. Smallpox: an historical review. Bull. Soc. Sci. Med. Grand-Duche Luxemb. 134:1997;31-51.
116. Berglund P., Smerdou C., Fleeton M.N., Tubulekas I., Liljestrom P. Enhancing immune responses using suicidal DNA vaccines. Nat. Biotechnol. 16:1998;562-565.
117. Mumper H.C.L.R.J. Jr., Rolland A.P., Tomlinson E. Lowrie D.B., Whalen R.G. DNA Vaccines Methods and Protocols. 2000;Humana, NJ.
118. Foldvari M., Attah-Poku S., Hu J., Li Q., Hughes H., Babiuk L.A., Kruger S. Palmitoyl derivatives of interferon alpha: potential for cutaneous delivery. J. Pharm. Sci. 87:1998;1203-1208.
119. Foldvari M.E.B.-E.M., He Z., Hu J., Attach-Poku S., King M. Dermal and transdermal delivery of protein pharmaceuticals: lipid based delivery systems for interferon alpha. Biotechnol. Appl. Biochem. 30:1999;129-137.
120. Scheuplein R.J. Percutaneous absorption after twenty-five years: or 'old wine in new wineskins'. J. Invest. Dermatol. 67:1976;31-38.
121. Muranishi S. Absorption enhancers. Crit. Rev. Ther. Drug Carrier Syst. 7:1990;1-33.
122. Elias P.M., Cooper E.R., Korc A., Brown B.E. Percutaneous transport in relation to stratum corneum structure and lipid composition. J. Invest. Dermatol. 76:1981;297-301.
123. Foldvari M., Gesztes A., Mezei M. Dermal drug delivery by liposome encapsulation: clinical and electron microscopic studies. J. Microencapsulation. 7:1990;479-489.
124. Lieb L.M., Liimatta A.P., Bryan R.N., Brown B.D., Krueger G.G. Description of the intrafollicular delivery of large molecular weight molecules to follicles of human scalp skin in vitro. J. Pharm. Sci. 86:1997;1022-1029.
125. Li L., Margolis L.B., Lishko V.K., Hoffman R.M. Product-delivering liposomes specifically target hair follicles in histocultured intact skin (letter). In Vitro Cell. Dev. Biol. 28A:1992;679-681.
126. Li L., Hoffman R.M. The feasibility of targeted selective gene therapy of the hair follicle. Nat. Med. 1:1995;705-706.
127. Felgner J.H., Kumar R., Sridhar C.N., Wheeler C.J., Tsai Y.J., Border R., Ramsey P., Martin M., Felgner P.L. Enhanced gene delivery and mechanism studies with a novel series of cationic lipid formulations. J. Biol. Chem. 269:1994;2550-2561.
128. Alexander M.Y., Akhurst R.J. Liposome-mediated gene transfer and expression via the skin. Hum. Mol. Genet. 4:1995;2279-2285.
129. Niemiec S.M., Latta J.M., Ramachandran C., Weiner N.D., Roessler B.J. Perifollicular transgenic expression of human interleukin-1 receptor antagonist protein following topical application of novel liposome-plasmid DNA formulations in vivo. J. Pharm. Sci. 86:1997;701-708.
130. Yu W.H., Kashani-Sabet M., Liggitt D., Moore D., Heath T.D., Debs R.J. Topical gene delivery to murine skin. J. Invest. Dermatol. 112:1999;370-375.
131. Tang D.C., Shi Z., Curiel D.T. Vaccination onto bare skin (letter). Nature. 388:1997;729-730.
132. Glenn G.M., Rao M., Matyas G.R., Alving C.R. Skin immunization made possible by cholera toxin (letter). Nature. 391:1998;851.
133. Glenn G.M., Scharton-Kersten T., Vassell R., Matyas G.R., Alving C.R. Transcutaneous immunization with bacterial ADP-ribosylating exotoxins as antigens and adjuvants. Infect. Immun. 67:1999;1100-1106.
134. Paul A., Cevc G., Bachhawat B.K. Transdermal immunisation with an integral membrane component, gap junction protein, by means of ultradeformable drug carriers, transfersomes. Vaccine. 16:1998;188-195.
135. Shi Z., Curiel D.T., Tang D.C. DNA-based non-invasive vaccination onto the skin (in process citation). Vaccine. 17:1999;2136-2141.
136. Fan H., Lin Q., Morrissey G.R., Khavari P.A. Immunization via hair follicles by topical application of naked DNA to normal skin. Nat. Biotechnol. 17:1999;870-872.